Thiopurines related malignancies in inflammatory bowel disease: Local experience in Granada, Spain

Table 1 Patients' characteristics n (%)

	Thiopurines (n = 429)	No thiopurines (n = 383)	P value
Age of diagnosis of IBD (yr)	30.85	40.13	< 0.001
Sex
Female	192	178	> 0.050
Male	237	205	> 0.050
Ulcerative colitis1	n = 130	n = 263	< 0.001
Extension
E1	5 (3.85)	51 (19.4)
E2	42 (32.3)	103 (39.2)
E3	83 (63.85)	109 (41.4)
Severity
S1	51 (39.2)	150 (57)
S2	58 (44.6)	102 (38.8)
S3	21 (16.2)	11 (4.2)
Crohn's disease2	n = 299	n = 120	< 0.001
Age of diagnosis (yr)
A1	33 (11)	6 (5)
A2	214 (71.6)	68 (56.7)
A3	52 (17.4)	46 (38.3)
Location
L1	137 (45.8)	46 (38.3)
L2	54 (18)	34 (28.3)
L3	96 (32.1)	39 (32.5)
L4	12 (4.1)	1 (0.8)
Behaviour
B1	155 (51.8)	105 (87.5)
B2	55 (18.4)	10 (8.3)
B3	89 (29.8)	5 (4.2)
P	73 (24.4)	15 (12.5)
Neoplasms	n = 17	n = 31	0.013

¹Patients with ulcerative colitis treated with thiopurines had more severity and disease extension;

²Patients with Chron's disease treated with thiopurines more usually had ileal or ileocholic location and an inflammatory or penetrating behaviour; Patients under thiopurine treatment had a lower age at diagnosis. IBD: Inflammatory bowel disease.